Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Apitegromab plus tirzepatide

INVESTIGATIONAL

Myostatin inhibition combined with GIP and GLP-1 receptor agonism

1
graded results
0
ongoing records
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Apitegromab plus tirzepatide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Lean-mass preservation during tirzepatide-associated weight loss; Co-administered intravenous apitegromab and subcutaneous tirzepatide; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Apitegromab plus tirzepatide INVESTIGATIONAL
body-composition Mixed
Very low evidence

Scholar Rock's phase 2 EMBRAZE trial (NCT06445075) tested apitegromab added to tirzepatide over 24 weeks and reported greater preservation of lean mass than...

Scholar Rock, EMBRAZE phase-2 topline press release, 18 Jun 2025; NCT06445075 Source
Full findingScholar Rock's phase 2 EMBRAZE trial (NCT06445075) tested apitegromab added to tirzepatide over 24 weeks and reported greater preservation of lean mass than tirzepatide alone. This is a muscle-preservation combination studied with tirzepatide rather than semaglutide. The available efficacy figures are sponsor-issued topline results and have not been peer reviewed.
PopulationEMBRAZE phase-2 RCT, N=102, double-blind placebo-controlled, 24 weeks, adults overweight/obese; apitegromab 10 mg/kg IV q4w + tirzepatide vs placebo + tirzepatide.
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo + tirzepatide